Drug Metabolism and Pharmacokinetics
Online ISSN : 1880-0920
Print ISSN : 1347-4367
ISSN-L : 1347-4367
Volume 27 , Issue 2
Showing 1-14 articles out of 14 articles from the selected issue
Editorial
Regular Articles
  • Takako FURUKAWA, Fumihiro NAKAMORI, Kazuhiro TETSUKA, Yoichi NARITOMI, ...
    Type: Regular Article
    2012 Volume 27 Issue 2 Pages 171-180
    Published: 2012
    Released: April 25, 2012
    [Advance publication] Released: October 04, 2011
    JOURNALS FREE ACCESS
      UDP-glucuronosyltransferase (UGT) is highly expressed in the small intestine and catalyzes the glucuronidation of small molecules, which may affect the oral bioavailability of drugs. However, no method of predicting the in vivo observed fraction of absorbed drug (FaFg) affected by UGT has yet been established. Here, we investigated the relationship between FaFg and in vitro clearance of nine UGT substrates (ketoprofen, tolcapone, telmisartan, raloxifene, entacapone, resveratrol, buprenorphine, quercetin, and ezetimibe) via UGT in intestinal microsomes (CLint, UGT) in rats. FaFg was calculated from pharmacokinetic parameters after intravenous and oral administration or using the portal-systemic concentration difference method, with values ranging from 0.027 (ezetimibe) to 1 (tolcapone). Glucuronides of model compounds were observed in the portal plasma after oral administration, with CLint, UGT values ranging from 57.8 (tolcapone) to 19,200 µL/min/mg (resveratrol). An inverse correlation between FaFg and CLint, UGT was observed for most compounds and was described using a simplified intestinal availability model reported previously. This model gave accurate predictions of FaFg values for three in-house compounds. Our results show that FaFg in rats is affected by UGT and can be predicted using CLint, UGT. This work should hasten the development of a method to predict FaFg in humans.
    Download PDF (293K)
  • Takafumi AKABANE, Nicolas GERST, Yoichi NARITOMI, Jeffrey N. MASTERS, ...
    Type: Regular Article
    2012 Volume 27 Issue 2 Pages 181-191
    Published: 2012
    Released: April 25, 2012
    [Advance publication] Released: October 25, 2011
    JOURNALS FREE ACCESS
      Human hepatocytes are a physiologically relevant tool useful in evaluating liver-related pharmacokinetics, including non-cytochrome P-450 (CYP) metabolism, due to their broad spectrum of metabolic enzyme activity. To verify the usefulness of human hepatocytes in evaluating non-CYP metabolism for drug discovery, we compared intrinsic clearance values (CLint) in freshly isolated and cryopreserved hepatocytes using 14 compounds primarily metabolized by non-CYP enzymes, including UDP-glucuronosyltransferase, carbonyl/aldo-keto reductase, aldehyde oxidase, flavin-containing monooxygenase, and monoamineoxidase. Cryopreservation resulted in a >20% reduction (maximum: 50%) in CLint in 7/14 compounds (statistically significant for 5 compounds) on comparing CLint values in freshly isolated and cryopreserved hepatocytes from the same donors (n = 4). However, the number of compounds with >20% CLint reduction decreased to 3 on comparing average of CLint values including un-matched donors (dolasetron: −27%, naltorexone: −32%, and phthalazine: −48%; statistically significant for phthalazine, n = 6–11). These findings suggest that fresh hepatocytes are useful in evaluating intact non-CYP enzyme activities. However, we must note that the reduction in CLint by cryopreservation could be rendered negligible if high-activity lots are selected for assay. We therefore recommend using cryopreserved hepatocytes for large-scale screening for non-CYP metabolism in drug discovery research considering the advantages in usability with cryopreserved hepatocytes.
    Download PDF (655K)
  • Tomomi KATO, Akinobu HAMADA, Shunsuke MORI, Hideyuki SAITO
    Type: Regular Article
    2012 Volume 27 Issue 2 Pages 192-199
    Published: 2012
    Released: April 25, 2012
    [Advance publication] Released: November 22, 2011
    JOURNALS FREE ACCESS
      The aim of this study was to investigate the impact of genetic polymorphisms in the metabolic and cellular transport pathway of methotrexate (MTX) on the clinical outcome of MTX monotherapy in Japanese rheumatoid arthritis (RA) patients. Fifty-five patients were treated with MTX monotherapy at a dose of 4–10 mg/week. The total concentration of MTX-polyglutamates (MTX-PGs) was measured at steady-state in red blood cells (RBCs) by high performance liquid chromatography. The genotype at 16 polymorphic sites in 11 genes (ABCB1, ABCG2, ABCC2, RFC1, PCFT, SLCO1B1, MTHFR, GGH, ATIC, MTR, and MTRR) was analyzed. No significant association between the total concentration of MTX-PGs in RBCs and clinical outcome was found. However, patients with the ABCB1 3435TT genotype had a significantly lower mean disease activity score (DAS) 28 than did patients with the ABCB1 3435CC genotype (p = 0.02). Similarly, patients with the ABCB1 2677AA/AT/TT genotypes had a significantly lower mean DAS28 than did patients with the ABCB1 2677GG/GA/GT genotypes (p = 0.04). The patients with the MTHFR 1298AA genotype had a significantly lower mean DAS28 than those with the MTHFR 1298AC/CC genotypes (p = 0.04). In conclusion, the ABCB1 3435C>T, ABCB1 2677G>A/T, and MTHFR 1298A>C polymorphisms influenced the efficacy of MTX monotherapy.
    Download PDF (417K)
  • Takeshi KUMAGAI, Hiroyuki SUZUKI, Takamitsu SASAKI, Shuhei SAKAGUCHI, ...
    Type: Regular Article
    2012 Volume 27 Issue 2 Pages 200-206
    Published: 2012
    Released: April 25, 2012
    [Advance publication] Released: November 10, 2011
    JOURNALS FREE ACCESS
      Aryl hydrocarbon receptor (AhR) activators have been shown to induce members of the cytochrome P450 (P450) 1 family. Here we demonstrate that the AhR activators induce CYP3A4 through human pregnane X receptor (PXR). AhR activators, polycyclic aromatic hydrocarbons (PAHs) and 2,3,7,8-tetrachlorodibenzo-p-dioxin (TCDD) increased CYP3A4 reporter activity and CYP3A4 mRNA expression in HepG2 cells. The CYP3A4 reporter activity was also increased by treatment with cigarette tar. The increased CYP3A4 reporter activity was clearly knocked down by the introduction of human PXR-small interfering RNA, but not by that of human AhR-small interfering RNA. The CYP3A4 reporter activity enhanced by overexpression of human PXR was further increased by treatment with PAHs and TCDD as well as by treatment with rifampicin. These results suggest that PAHs contained in cigarette smoke induce CYP3A4 in human liver.
    Download PDF (1006K)
  • Ryosuke SHIMIZU, Makoto MIYAZAKI, Kazunori IWANAGA, Masawo KAKEMI
    Type: Regular Article
    2012 Volume 27 Issue 2 Pages 207-215
    Published: 2012
    Released: April 25, 2012
    [Advance publication] Released: November 10, 2011
    JOURNALS FREE ACCESS
      The interactive hypotensive effect of the combination treatment of losartan (LOS) and hydrochlorothiazide (HCTZ) was assessed using a pharmacokinetic-pharmacodynamic (PK-PD) model in spontaneously hypertensive rats. Intravenous coadministration of these drugs showed a prolonged and enhanced time-course of the hypotensive effect. A population PK analysis revealed the delayed elimination of LOS after coadministration. The time-course of the plasma renin activity (PRA) was measured, and showed a more continuative time profile after coadministration compared with the administration of LOS alone. An indirect response model was applied to describe the relationship between the PK of LOS and the PRA profile, and the Emax value for the increase of the PRA by LOS was increased with the dose of HCTZ. Blood pressure was linked to the PRA through an effect compartment. The model successfully described the relationship between the doses of LOS and HCTZ and their interactive hypotensive effect. These results indicate that the interaction for blood pressure in the combination treatment of LOS and HCTZ can be estimated using the doses of the drugs and the PRA-mediated PK-PD model.
    Download PDF (915K)
  • Jin Sook SONG, Kyeong-Ryoon LEE, Hyun Jin KWON, Sang Dal RHEE, Min Sun ...
    Type: Regular Article
    2012 Volume 27 Issue 2 Pages 216-222
    Published: 2012
    Released: April 25, 2012
    [Advance publication] Released: January 13, 2012
    JOURNALS FREE ACCESS
      KR-66223 is a novel dipeptidyl peptidase-4 (DPP-4) inhibitor that is under development for the treatment of type 2 diabetes. We studied the pharmacokinetic and pharmacodynamic characteristics of KR-66223 in rats, monkeys, and dogs to predict PK/PD profiles in humans. KR-66223 exhibited a moderate volume of distribution (0.3–1.8 L/kg), moderate systemic clearance (1–1.76 L/h/kg), long half-life (>3 h), and low oral bioavailability (below 2.5% in all tested species). The EC50s for DPP-4 inhibition as calculated by the Emax model was below 4.25 ng/mL across all species, confirming KR-66223 as a potent DPP-4 inhibitor. In vitro plasma protein binding suggested that it was available (69–89%), correlating with its volume of distribution in animals. Using allometric scaling and the Emax model, human systemic clearance, volume of the central compartment, volume of the peripheral compartment, and EC50 for DPP-4 inhibition were predicted to be 0.31 L/h/kg, 0.1 L/kg, 2.4 L/kg, and 3 ng/mL, respectively. These results can serve as a valuable foundation for future clinical trials.
    Download PDF (654K)
  • Mitsuhiro NISHIHARA, Miyako SUDO, Hidenori KAMIGUCHI, Naohiro KAWAGUCH ...
    Type: Regular Article
    2012 Volume 27 Issue 2 Pages 223-231
    Published: 2012
    Released: April 25, 2012
    [Advance publication] Released: November 29, 2011
    JOURNALS FREE ACCESS
      Sipoglitazar is a novel anti-diabetic agent with triple agonistic activities on the human peroxisome proliferator-activated receptors, hPPAR-γ, -α, and -δ. The bioavailability for sipoglitazar was 95.0% and 72.6% in rats and monkeys respectively and sipoglitazar is hardly subject to first pass metabolism in either species. Following oral administration of [14C]sipoglitazar to rats, sipoglitazar and its metabolites were distributed to the rat tissues with relatively high concentrations in the liver and also to the target tissue, the adipose tissue. The major component was sipoglitazar in the plasma of rats and monkeys. In rats, sipoglitazar was mainly excreted into the feces via biliary excretion as sipoglitazar-G, while the major component was M-I-G in the urine and M-I in the feces of monkeys. In hepatocytes, the metabolism was not extensively advanced in rats and the main metabolites were M-I and sipoglitazar-G in humans, similar to the metabolic profile in monkeys. There was no metabolite specific for humans in vitro. In conclusion, the formation of M-I, M-I-G and sipoglitazar-G is considered to be crucial and sipoglitazar is presumed to be cleared primarily by oxidation and glucuronidation in humans, when examined in vivo and in vitro.
    Download PDF (769K)
  • Xinjin GUO, Qiang MENG, Qi LIU, Changyuan WANG, Qi MAO, Huijun SUN, Ji ...
    Type: Regular Article
    2012 Volume 27 Issue 2 Pages 232-241
    Published: 2012
    Released: April 25, 2012
    [Advance publication] Released: November 29, 2011
    JOURNALS FREE ACCESS
      The purpose of this study was to clarify the pharmacokinetic mechanism of interaction between JBP485 (cyclo-trans-4-L-hydroxyprolyl-L-serine, a dipeptide with antihepatitis activity) and lisinopril (an angiotensin-converting enzyme inhibitor) in vitro and in vivo. When JBP485 and lisinopril were administered orally simultaneously, the plasma concentrations of the two drugs were decreased significantly, but few changes were observed after simultaneous intravenous administration of the two drugs. The uptake of JBP485 and lisinopril in everted intestinal sacs and in HeLa cells transfected with human peptide cotransporter 1 (PEPT1), as well as absorption of JBP485 and lisinopril after jejunal perfusion were reduced after simultaneous drug administration, which suggested that the first target of drug interaction was PEPT1 in the intestine during the absorption process. The cumulative urinary excretions and renal clearance of the two drugs were decreased after intravenous co-administration, while uptakes of the two drugs in kidney slices and hOAT1/hOAT3-transfected HEK293 cells were decreased. These results indicated that the second target of drug-drug interaction was located in the kidney. These findings confirmed that the pharmacokinetic mechanism of interaction between JBP485 and lisinopril could be explained by their inhibition of the same transporters in the intestinal mucosa (PEPT1) and kidneys (OATs).
    Download PDF (1840K)
  • Kanoko EGASHIRA, Hitoshi SASAKI, Shun HIGUCHI, Ichiro IEIRI
    Type: Regular Article
    2012 Volume 27 Issue 2 Pages 242-247
    Published: 2012
    Released: April 25, 2012
    [Advance publication] Released: November 29, 2011
    JOURNALS FREE ACCESS
      Tacrolimus is a well-known potent immunosuppressant agent, which has various drug-drug or food-drug interactions. Previously, we found a renal transplant recipient who increased tacrolimus blood concentrations after ingestion of pomelo as a rare case. So, we investigated the effect of pomelo after its administration for one day or 3 consecutive days on the pharmacokinetics of tacrolimus in rats. We also confirmed the effects of grapefruit, turmeric, and ginger. The tacrolimus blood concentrations of the rats pre-treated with 100% pomelo juice were significantly higher than those pre-treated with water. On the other hand, the tacrolimus blood concentrations of the rats pre-treated with 50% pomelo juice were not significantly different from those pre-treated with water. The pomelo-tacrolimus interaction showed concentration dependency. Even low concentration of pomelo juice could enhance the blood concentrations of tacrolimus by repeated administration. The inhibitory effect of 100% pomelo juice disappeared 3 days after intake. The AUC values of tacrolimus in the rats pre-treated with grapefruit juice, ginger juice, and turmeric juice were significantly larger than those pre-treated with water. We could confirm the pomelo-tacrolimus interaction, which we discovered in a case study, quantitatively. We newly found the influence of turmeric and ginger on tacrolimus pharmacokinetics, comparable to pomelo.
    Download PDF (430K)
  • Tatsuya YAGI, Takafumi NAITO, Yasuaki MINO, Kazuo UMEMURA, Junichi KAW ...
    Type: Regular Article
    2012 Volume 27 Issue 2 Pages 248-254
    Published: 2012
    Released: April 25, 2012
    [Advance publication] Released: January 13, 2012
    JOURNALS FREE ACCESS
      The aim of this open-label, randomized, and 3-period crossover study was to evaluate the influences of concomitant antacid administration on the plasma disposition, intestinal absorption, and urinary excretion of gabapentin in humans. Gabapentin (200 mg) was orally administered alone, with 1 g magnesium oxide (MgO), or with 20 mg omeprazole to 13 healthy adult subjects. Oral bioavailability (BA) of gabapentin was estimated by 24-h urine collection. The Cmax, Tmax and AUC0–∞ of gabapentin + MgO were significantly lower than that of gabapentin alone (by 33%, 36% and 43%, respectively) and gabapentin + omeprazole (by 29%, 46% and 40%, respectively). In contrast, no significant differences were observed in the plasma disposition parameters of gabapentin between the treatments with and without omeprazole. The gabapentin BA in the MgO treatment was significantly lower, by 32% and 39%, compared to the gabapentin alone and with omeprazole treatment, respectively. There was no significant difference in the gabapentin BA between the gabapentin alone and with omeprazole treatment. Concomitant MgO and omeprazole did not affect the renal clearance of gabapentin. In conclusion, concomitant MgO decreased the gabapentin exposure through the reduction of intestinal absorption extent and rate. This reduction may be independent of the suppression of gastrointestinal acidification caused by antacids.
    Download PDF (329K)
  • Masahiko OHKUBO, Kinya OHTA, Katsuhisa INOUE, Hiroaki YUASA
    Type: Regular Article
    2012 Volume 27 Issue 2 Pages 255-262
    Published: 2012
    Released: April 25, 2012
    [Advance publication] Released: November 29, 2011
    JOURNALS FREE ACCESS
      Recent studies have identified monocarboxylate transporter 1 (MCT1), sodium-coupled monocarboxylate transporter 1 (SMCT1) and SMCT2 as those that may be involved in the carrier-mediated intestinal absorption of nicotinate, but their roles have not been fully clarified yet. To address the issue, we examined the uptake of nicotinate in the rat small intestine by using everted tissue sacs. The uptake of nicotinate was Na+-dependent and saturable at pH 7.4 in both the jejunum and ileum. The saturable transport consisted of a single component with the Michaelis constant (Km) of 1.18 mM in the jejunum, while in the ileum it consisted of the high and the low affinity components with the Km values of 8.62 µM and 2.36 mM, respectively, and the latter was prevailing in transport capacity and similar to the jejunal transport component. Nicotinate uptake activity attributable to a H+-dependent transporter like MCT1 was, however, only minimal in the two intestinal sites. These results suggest that a low affinity type of SMCT2-like transporter would be in operation with high capacity throughout the small intestine, playing the role as the major intestinal nicotinate uptake transporter, and a high affinity type of SMCT1-like transporter would be additionally in operation in the ileum.
    Download PDF (528K)
Note
  • Hideki HAYASHI, Yui TAZOE, Masato HORINO, Chihiro FUJIMAKI-KATOH, Seij ...
    Type: Note
    2012 Volume 27 Issue 2 Pages 263-267
    Published: 2012
    Released: April 25, 2012
    [Advance publication] Released: December 27, 2011
    JOURNALS FREE ACCESS
      A novel single-nucleotide polymorphism (SNP) in the 3′-untranslated region of the human dihydrofolate reductase (DHFR) gene with enhanced expression was identified in 2001. In 2007, it was reported that this SNP, DHFR C829T, was located close to a microRNA binding site and contributed to the stability of mRNA. Many researchers have analyzed this SNP in several races including Asians and Caucasians. However, the mutation allele is not yet confirmed in most populations. In this study, we reinvestigated the frequency of this SNP using three methods. First, this SNP in genomic DNA was analyzed by a PCR-restriction fragment length polymorphism method. Second, this SNP in mRNA was analyzed by a single nucleotide extension method following a reverse transcription reaction. Third, the mRNA expression level was analyzed by a real-time PCR method. The findings in our study, regarding the discovery of this SNP, suggest that the SNP is an artifact caused by contamination by the genomic DNA of the pseudogene DHFRP1. This study is a reinvestigation of a newly discovered genetic polymorphism.
    Download PDF (923K)
SNP Communication
  • Jonathan D. URBAN, Robert A. BUDINSKY, J. Craig ROWLANDS
    Type: SNP Communication
    2012 Volume 27 Issue 2 Pages 268-278
    Published: 2012
    Released: April 25, 2012
    [Advance publication] Released: December 20, 2011
    JOURNALS FREE ACCESS
      Single nucleotide polymorphisms (SNPs) in genes coding for proteins that maintain the cytosolic aryl hydrocarbon receptor (AHR) complex may affect individual susceptibility to dioxin-like compound (DLC)-induced toxicity. The cytosolic 90 kDa heat shock proteins (HSP90s) are ubiquitous chaperone proteins that bind to and stabilize numerous client proteins, including non-ligand-bound AHR. The objective of this study was to characterize SNPs in the human cytosolic HSP90 genes (HSP90AA1 and HSP90AB1). DNA sequencing of 101 human samples detected eight and seven unique SNPs at the HSP90AA1 and HSP90AB1 loci, respectively. For HSP90AA1, two non-synonymous (L71M and E554D) and one rare early termination (Q107X) SNP were observed. One SNP (E554D) was a rare novel polymorphism located in the middle substrate binding region. All SNPs detected in the HSP90AB1 gene were synonymous. With the exception of Q107X, in silico analyses predicted all HSP90 SNPs would have very low to medium risk of affecting the regulation of alternative splicing in gene transcription or protein function. Overall, a very limited presence of SNPs with predicted functional consequence in key domains of the human HSP90 proteins was observed in this study.
    Download PDF (278K)
feedback
Top